Skip to main content
SpringerLink
Log in

Review of clinical results of charged-particle therapy for esophageal cancer

  • Review Article
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Esophageal cancer is one of the common causes of cancer-related death. The treatment for esophageal cancer, particularly unresectable cases, is a difficult problem. Reports about charged-particle therapy including proton beam therapy and carbon-ion radiotherapy for esophageal cancer have increased. The objective of this study was to review the clinical results of charged-particle therapy for esophageal cancer. Charged-particle therapy was used with an expectation of increasing overall survival with reducing toxicities because charged-particle therapy can reduce the irradiated dose for normal tissues around the target tumor due to its characteristics, hence the name Bragg peak. Proton beam therapy showed a superior distribution of irradiation dose over X-ray therapy including intensity-modulated radiotherapy in silico, but clinical results were not the same. Some reports suggested that proton beam therapy may reduce acute and late toxicities, particularly in the heart and lung, during and after treatment, although it cannot lead to a higher overall survival than that in X-ray therapy. On the other hand, there are a few reports about carbon-ion radiotherapy for esophageal cancer. The special feature of carbon-ion radiotherapy is that hypofractionated radiotherapy is possible as compared to that in X-ray therapy or proton beam therapy. However, the true clinical impact of proton beam therapy or carbon-ion radiotherapy remains unclear because there are no prospective clinical trials comparing charged-particle therapy to X-ray therapy. In view of charged-particle therapy may become one of the treatment choices for esophageal cancer, further studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  2. Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam Physician. 2017;95(1):22–8.

    PubMed  Google Scholar 

  3. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.

    Article  PubMed  Google Scholar 

  4. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.

    Article  PubMed  Google Scholar 

  5. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.

    Article  CAS  PubMed  Google Scholar 

  6. Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21(14):2697–702.

    Article  CAS  PubMed  Google Scholar 

  7. Endo M, Robert R. Wilson (1914–2000): the first scientist to propose charged particle therapy-use of particle beam for cancer treatment. Radiol Phys Technol. 2018;11(1):1–6.

    Article  PubMed  Google Scholar 

  8. Miller DW. A review of proton beam radiation therapy. Med Phys. 1995;22(11 Pt 2):1943–54.

    Article  CAS  PubMed  Google Scholar 

  9. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25(8):953–64.

    Article  PubMed  Google Scholar 

  10. Particle therapy facilities in clinical operation. 2019. https://www.ptcog.ch/index.php/facilities-in-operation. Accessed 4 Nov 2019.

  11. Castro JR, Chen GT, Pitluck S, et al. Helium charged-particle radiotherapy of locally advanced carcinoma of the esophagus, stomach, and biliary tract. Am J Clin Oncol. 1983;6(6):629–37.

    Article  CAS  PubMed  Google Scholar 

  12. Linstadt DE, Castro JR, Phillips TL. Neon ion radiotherapy: results of the phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 1991;20(4):761–9.

    Article  CAS  PubMed  Google Scholar 

  13. Ma CM, Lomax T. Proton and carbon ion therapy. Florida: CRC Press; 2012.

    Book  Google Scholar 

  14. Walenta S, Mueller-Klieser W. Differential superiority of heavy charged-particle irradiation to X-rays: studies on biological effectiveness and side effect mechanisms in multicellular tumor and normal tissue models. Front Oncol. 2016;6:30.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Frandsen J, Boothe D, Gaffney DK, et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer. J Gastrointest Oncol. 2015;6(5):516–23.

    PubMed  PubMed Central  Google Scholar 

  16. Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol. 2010;95(2):240–4.

    Article  PubMed  Google Scholar 

  17. Cui Z, Tian Y, He B, et al. Associated factors of radiation pneumonitis induced by precise radiotherapy in 186 elderly patients with esophageal cancer. Int J Clin Exp Med. 2015;8(9):16646–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Tanabe S, Myojin M, Shimizu S, et al. Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields. J Radiat Res. 2013;54(6):1085–94.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hayashi K, Fujiwara Y, Nomura M, et al. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol. 2015;88(1046):20140168.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707–14.

    Article  PubMed  Google Scholar 

  21. Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2015;56(3):568–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hirano Y, Onozawa M, Hojo H, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2018;13(1):23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Shiraishi Y, Xu C, Yang J, et al. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or intensity-modulated radiation therapy. Radiother Oncol. 2017;125(1):48–544.

    Article  PubMed  Google Scholar 

  24. Sugahara S, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys. 2005;61(1):76–84.

    Article  PubMed  Google Scholar 

  25. Ono T, Nakamura T, Azami Y, et al. Clinical results of proton beam therapy for twenty older patients with esophageal cancer. Radiol Oncol. 2015;49(4):371–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lin SH, Komaki R, Liao Z, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):e345–351.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ishikawa H, Hashimoto T, Moriwaki T, et al. Proton beam therapy combined with concurrent chemotherapy for esophageal cancer. Anticancer Res. 2015;35(3):1757–62.

    PubMed  Google Scholar 

  28. Takada A, Nakamura T, Takayama K, et al. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Cancer Med. 2016;5(3):506–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ono T, Wada H, Ishikawa H, et al. Clinical results of proton beam therapy for esophageal cancer: multicenter retrospective study in Japan. Cancers (Basel). 2019;11(7):pii:E993.

    Article  CAS  Google Scholar 

  30. Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;99(3):667–76.

    Article  PubMed  Google Scholar 

  31. Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39(10):638–43.

    Article  PubMed  Google Scholar 

  32. Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81(3):684–90.

    Article  CAS  PubMed  Google Scholar 

  33. Ariga H, Nemoto K, Miyazaki S, et al. Prospective comparison of surgery alone and chemoradiotherapy with selective surgery in resectable squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2009;75(2):348–56.

    Article  PubMed  Google Scholar 

  34. Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106(4):407–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013;86(5):885–91.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lin SH, Hobbs BP, Verma V, et al. Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.19.02503.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Fang P, Shiraishi Y, Verma V, et al. Lymphocyte-sparing effect of proton therapy in patients with esophageal cancer treated with definitive chemoradiation. Int J Part Ther. 2018;4(3):23–322.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. Adv Radiat Oncol. 2019;4(1):63–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Warren S, Hurt CN, Crosby T, et al. Potential of proton therapy to reduce acute hematologic toxicity in concurrent chemoradiation therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2017;99(3):729–37.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018;128(1):154–60.

    Article  PubMed  Google Scholar 

  41. Hatogai K, Yano T, Kojima T, et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Sato D, Motegi A, Kadota T, et al. Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrence. Esophagus. 2020. https://doi.org/10.1007/s10388-020-00715-y.

    Article  PubMed  Google Scholar 

  43. Kumagai K, Mariosa D, Tsai JA, et al. Systematic review and meta-analysis on the significance of salvage esophagectomy for persistent or recurrent esophageal squamous cell carcinoma after definitive chemoradiotherapy. Dis Esophagus. 2016;29(7):734–9.

    Article  CAS  PubMed  Google Scholar 

  44. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.

    Article  CAS  PubMed  Google Scholar 

  45. Song T, Liang X, Fang M, et al. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev Anticancer Ther. 2015;15(10):1157–69.

    Article  CAS  PubMed  Google Scholar 

  46. Chen Y, Zhu HP, Wang T, et al. What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis. Oncotarget. 2017;8(51):89095–107.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Luo HS, Huang HC, Lin LX. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis. Radiat Oncol. 2019;14(1):178.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Akutsu Y, Yasuda S, Nagata M, et al. A phase I/II clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus. J Surg Oncol. 2012;105(8):750–5.

    Article  PubMed  Google Scholar 

  49. Isozaki Y, Yasuda S, Akutsu Y, et al. Salvage Carbon-ion radiotherapy for isolated lymph node recurrence following curative resection of esophageal cancer. Anticancer Res. 2018;38(11):6453–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. QST Hospital, 4-9-1 Anagawa, Inage-ku, Chiba-City, Chiba, 263-8555, Japan

    Takashi Ono

  2. Department of Radiation Oncology, Faculty of Medicine, Yamagata University, 2-2-2, Iida-Nishi, Yamagata, Japan

    Takashi Ono

Authors
  1. Takashi Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takashi Ono.

Ethics declarations

Conflict of interest

There is no conflict of interest to declare.

Ethical statement

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ono, T. Review of clinical results of charged-particle therapy for esophageal cancer. Esophagus 18, 33–40 (2021). https://doi.org/10.1007/s10388-020-00759-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-020-00759-0

Keywords

Search

Navigation